Ultrasound contrast agent developer Acusphere has begun a phase III clinical study of its AI-700 agent, which is designed for the detection of coronary artery disease in patients with ischemic heart disease. The phase III clinical program began recently with a pilot study to ensure that the clinical sites are familiarized with AI-700 imaging techniques, according to the Watertown, MA-based vendor. Two concurrent international trials are scheduled to follow the pilot study, Acusphere said.
By AuntMinnie.com staff writers
February 26, 2003
Related Reading
Acusphere raises $15 million, July 24, 2002
Acusphere US contrast agent research presented at ASE, July 19, 2001
Copyright © 2003 AuntMinnie.com
